Skip to main content

Table 2 Evidence on the skeletal effects of Ejiao Qianggu oral liquid (EJQG)

From: Ejiao as a preventive agent for osteoporosis - a scoping review of current evidence

Researchers

Composition of prescription

Study Design

Findings

Shen et al. (2005) [41]

Ejiao, cooked ground Radix Rehmanniae Preparata, Codonopsis pilosula, Astragalus membranaceus, Lycium barbarum, Ostrea gigas

Animals: 3-month-old Wistar rats (male & female n = 30)

Cells: Osteoblasts from newborn Sprague-Dawley rats

Treatment: EJQG-medicated serum (100, 500, 1000 g/L) applied to osteoblasts

Negative control: Standard culture medium (untreated)

Positive control: tibolone-medicated serum (100, 1000 g/L)

Osteoblast proliferation: ↑ (vs. untreated control)

Osteocalcin levels: ↑ (vs. untreated control)

OPG mRNA expression: ↑ (vs. untreated control)

RANKL mRNA expression: ↓ (vs. untreated control)

Shen et al. (2005) [23]

Ejiao, cooked ground Radix Rehmanniae Preparata, Codonopsis pilosula, Astragalus membranaceus, Lycium barbarum, Ostrea gigas

Animals: 3-month-old Wistar rats (male & female)

Cells: Osteoblasts from newborn Sprague-Dawley rats

Treatment: Serum from Wistar rats supplemented with EJQG (100, 500, 1000 g/L) for 7 days was applied to primary osteoblasts

Untreated control: culture medium

Positive control: tibolone (100, 1000 g/L)

Osteoblast proliferation: ↑ vs. untreated control

Bone Gla protein levels: ↑ vs. untreated control

OPG mRNA expression: ↑ at 1000 g/L vs. untreated control

RANKL mRNA expression: ↓ at 1000 g/L vs. untreated control

Li et al. (2006) [47]

Ejiao, cooked ground Radix Rehmanniae Preparata, Codonopsis pilosula, Astragalus membranaceus, Lycium barbarum, Ostrea gigas

Animals: Sprague-Dawley rats (3 months old)

Model: Closed mid-shaft tibial fracture model without fixation

Treatment: EJQG (2 mL/rat, p.o.) twice daily

Negative control: Normal saline, twice daily

Positive control: Jiegu Qili tablets (0.45 g/2 mL, p.o.) twice daily

Evaluation periods: 4, 7, 14, 21 & 28 days post-fracture

VEGF Expression:

EJQG Group: ↑ vs. negative control on day 7

FGF-2 Expression:

EJQG Group: ↑ vs. negative control on day 14

Li et al. (2007) [48]

Ejiao, cooked ground Radix Rehmanniae Preparata, Codonopsis pilosula, Astragalus membranaceus, Lycium barbarum, Ostrea gigas

Animals: Female Sprague-Dawley rats (3 months old)

Model: Tibial fracture induced via three-point bending

Treatment: EJQG (2 mL twice daily, p.o.)

Negative control: Normal saline

Positive control: Qili Linking Bone Pill (225 g/L, 2 mL, p.o. twice daily)

Evaluation: VEGF and FGF-2 expression on days 4, 7, 14, 21, 28 post-fracture via immunohistochemistry

VEGF Expression:

EJQG Group ↑ on day 14 vs. negative control

FGF-2 Expression:

EJQG Group ↑ on day 7 vs.

negative control

Wu et al.

2007 [43]

Ejiao, cooked ground Radix Rehmanniae Preparata, Codonopsis pilosula, Astragalus membranaceus, Lycium barbarum, Ostrea gigas

Osteoblasts cells.

Negative control: NA

Positive control: NA

Proliferation:

EJQG serum:↑ S-phase cells, ↑ proliferation index.

Calcium Uptake: EJQG serum: ↑ intracellular Ca²⁺

Mineralisation:

High-dose serum: ↑ calcified nodule formation (P < 0.05).

Wu et al. (2007) [42]

Ejiao, cooked ground Radix Rehmanniae Preparata, Codonopsis pilosula, Astragalus membranaceus, Lycium barbarum, Ostrea gigas

Cells: 24-h-old Sprague-Dawley rats’ calvarial osteoblasts

Treatment: EJQG (low, 100 mL, medium: 500 mL, high, 1000 mL, p.o.)

Untreated control: normal saline

Positive control: NA

Osteoblast proliferation: ↑ vs. untreated control

Alkaline Phosphatase Activity: ↑ vs. untreated control

Mineralisation: medium group ↑ vs. untreated control

Shuai et al. (2008) [44]

Ejiao, cooked ground Radix Rehmanniae Preparata, Codonopsis pilosula, Astragalus membranaceus, Lycium barbarum, Ostrea gigas

Animals: 4-month-old female Sprague-Dawley rats

Disease Model; OVX-induced osteoporosis

Treatment: EJQG 2 mL, p.o., twice daily

Negative control: Normal saline

Positive control: NA

BMD: ↑ vs. negative control

Biomechanical strength: ↑ vs. negative control

25(OH)D3 and 1,25(OH)2D3 levels: ↑ vs. negative control

Guo et al. (2009) [45]

Ejiao, cooked ground Radix Rehmanniae Preparata, Codonopsis pilosula, Astragalus membranaceus, Lycium barbarum, Ostrea gigas

Animals: 6-month-old female Sprague-Dawley rats

Disease Model: OVX-induced osteoporosis

Treatment: 2 mL of EJQG, p.o., twice daily for 6 months

Negative control: Normal saline

Positive control: NA

25-OH-VD3 levels: ↑ vs. negative control

1,25-(OH)2-VD3 levels: ↑ vs. negative control

VDR gene expression: ↑ vs. negative control

Guo et al. (2009) [46]

Ejiao, cooked ground Radix Rehmanniae Preparata, Codonopsis pilosula, Astragalus membranaceus, Lycium barbarum, Ostrea gigas

Animals: 6-month-old Female Sprague-Dawley rats

Disease Model, OVX

Treatment: 2 mL of EJQG p.o., twice daily for 6 months

Negative control: Normal saline

Positive control: NA

Type I collagen protein and mRNA levels: ↑ vs. negative control

Wang et al. (2021) [49]

Ejiao, cooked ground Radix Rehmanniae Preparata, Codonopsis pilosula, Astragalus membranaceus, Lycium barbarum, Ostrea gigas

Patients: 128 older adults with osteoporosis (mean age: 69.52 ± 1.31 years)

Groups:

Treatment group:

n = 64 (36 men, 28 women)

Mean age: 71.22 ± 1.01 years old

Treatment: EJQG + Calcitriol (10 mL, 3 times daily), p.o.

Control group:

n = 64 (35 men, 29 females) Mean age: 68.60 ± 1.03 years old

Treatment: Calcitriol (1 capsule of 0.25 µg, twice daily), p.o.

Duration: 3 months

Effective rate:

Treatment group: ↑ vs. control group

Symptom improvement time: ↑ vs. control group

Low back pain: ↓ vs. control group

Bone pain: ↓ vs. control group

Lower limb weakness: ↓ vs. control group

Muscle cramps: ↓vs control group

BMD: ↑ vs. control group

  1. Abbreviations: 1,25(OH)2D3, 1,25-Dihydroxyvitamin D3; 25(OH)D3, 25-Hydroxyvitamin D3; BGP, Bone Gla protein; BMD, Bone mineral density; DGRBOS, Donkey-hide glue reinforcing bone oral solution; FGF-2, Fibroblast growth factor 2; p.o., per-oral; OPG, Osteoprotegerin; OVX, Ovariectomised; RANKL, Receptor activator of nuclear factor kappa-B ligand; VEGF, Vascular endothelial growth factor; VDR, Vitamin D Receptor; ↑, increase or upregulate↓, decrease or downregulate